Sep 30, 2021 / 04:40PM GMT
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research
Alethia Young here. I cover large-cap, small mid-cap biotech at Cantor. I'm very happy to have Aurinia here with us. I have Peter Greenleaf, who is the CEO of the company. And we're doing a fireside chat for almost all of this.
Questions and Answers:
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare ResearchAnd why don't I just start off, Peter, with you kind of framing, I mean you have your first drug approved on the market. So just tell us a little bit about how the past 12 months has been going.
Peter S. Greenleaf - Aurinia Pharmaceuticals Inc. - President, CEO & Director
Yes. So just to start, for folks that may not know the company, we are -- the company has been around for about 10 years. And it was a development-stage company up until about -- just about 1.5 years ago, where we produced data in the
Trustpilot
